Does Network Health Cover Adderall?

What Is Network Health and How Does Its Drug Coverage Work?

Network Health is a regional health plan based in Menasha, Wisconsin, offering commercial, Medicare Advantage, and marketplace plans primarily across Wisconsin. Its prescription drug benefits follow a tiered formulary structure, where generic drugs sit at lower tiers and brand-name drugs occupy higher tiers with larger cost-shares.

Adderall (amphetamine/dextroamphetamine mixed salts) is a Schedule II controlled substance approved by the FDA for attention-deficit/hyperactivity disorder (ADHD) in children aged 3 and older and in adults. FDA prescribing information is publicly available via the FDA label database. Because it is a controlled substance, coverage rules are stricter than for non-scheduled medications.

Tiered Formulary Basics

Most Network Health plans use a 4- or 5-tier formulary:

• Tier 1: Preferred generics (lowest cost-share)
• Tier 2: Non-preferred generics or preferred brands
• Tier 3: Non-preferred brands
• Tier 4 to 5: Specialty or excluded drugs

Generic mixed amphetamine salts typically land at Tier 2, while brand-name Adderall XR frequently sits at Tier 3 or higher. ADHD is among the most common diagnoses driving prescription drug utilization in the United States. The CDC estimates that as of 2022, approximately 7 million children (11.4% of U.S. Children aged 3 to 17) have received an ADHD diagnosis, and adult diagnoses continue to rise. CDC ADHD data are available at cdc.gov.

Schedule II Controls and Supply Limits

Federal law restricts Schedule II prescriptions to a 30-day supply per fill with no automatic refills. Network Health, like all U.S. Insurers, cannot override this federal ceiling. The DEA's scheduling of amphetamines under the Controlled Substances Act means your pharmacy cannot dispense more than a 30-day quantity even if your plan would otherwise allow 90-day fills for maintenance drugs. DEA scheduling information is available through the DEA's diversion control division.

Does Network Health Require Prior Authorization for Adderall?

Prior authorization (PA) is almost always required for Adderall and generic mixed amphetamine salts on Network Health plans, particularly for adults and for doses above standard thresholds.

PA is a process where your prescribing clinician submits clinical documentation to the insurer before the plan agrees to pay. Without an approved PA, the pharmacy will decline to process the claim at the insurance rate, and you pay full cash price.

What Triggers a PA Request?

Network Health's PA criteria for stimulant medications generally include:

1. A documented DSM-5 diagnosis of ADHD (code F90.0, F90.1, or F90.2)
2. Prescriber confirmation that non-pharmacological interventions have been considered
3. Age verification (adult PA criteria differ from pediatric criteria)
4. Dose within FDA-labeled range (5 to 60 mg/day for immediate-release; up to 30 mg/day for XR formulations in adults)

The American Academy of Pediatrics 2019 ADHD clinical practice guideline recommends medication plus behavior therapy as first-line treatment for children 6 and older, and medication alone for adolescents and adults when behavior therapy is not feasible. The full AAP guideline is indexed on PubMed. Insurers including Network Health typically align PA criteria with this guideline framework.

How Long Does PA Approval Take?

Standard PA decisions must be returned within 72 hours under federal managed care rules, or within 24 hours for urgent requests. The Centers for Medicare and Medicaid Services (CMS) finalized updated prior authorization rules in January 2024 requiring faster turnaround times and electronic PA for many plans. CMS PA rule summary is available at cms.gov.

If you are switching to Network Health mid-treatment, ask your prescriber to submit the PA the same week as your enrollment date to avoid a gap in medication.

What If PA Is Denied?

A denial triggers your right to appeal. Under the Affordable Care Act and the Employee Retirement Income Security Act (ERISA), members have the right to an internal appeal and, if that fails, an external review by an independent organization. Federal external review standards are outlined at healthcare.gov and referenced in 45 CFR §147.136. Your prescriber's office can submit supporting documentation, including neuropsychological testing results or prior treatment records, to strengthen an appeal.

What Does Adderall Cost With Network Health Coverage?

Actual out-of-pocket costs depend on your specific plan, whether you have met your annual deductible, and whether the drug is generic or brand.

Generic Mixed Amphetamine Salts Cost Estimates

For a 30-day supply of generic mixed amphetamine salts (immediate-release, 20 mg):

| Plan Type | Before Deductible | After Deductible Met | |---|---|---| | Commercial HMO (Tier 2) | $30, $50 | $10, $20 copay | | Marketplace Silver (Tier 2) | $40, $60 | $15, $25 copay | | Medicare Advantage Part D | Varies by plan phase | $5, $35 typical |

These are estimates. Verify your exact cost-share in your Summary of Benefits and Coverage (SBC) document or through Network Health's online pharmacy cost estimator.

Brand-Name Adderall XR Cost Estimates

Brand Adderall XR at Tier 3 on a standard commercial plan commonly costs $80, $150 for a 30-day supply before deductible. Shire (now Takeda) has offered a savings card for Adderall XR that reduces out-of-pocket costs for commercially insured patients, but these cards cannot be used with federal insurance programs (Medicare, Medicaid). Always check whether a manufacturer coupon is available at the brand's official site.

The Adderall Shortage and Its Effect on Coverage Claims

The FDA declared an Adderall shortage beginning in October 2022, driven by manufacturing constraints and a post-pandemic surge in diagnoses. The FDA shortage database entry for amphetamine mixed salts is at FDA.gov. During shortage periods, pharmacies may be unable to fill prescriptions regardless of insurance approval. Network Health members experiencing this issue can request a formulary exception to substitute a therapeutically equivalent stimulant such as lisdexamfetamine (Vyvanse) or methylphenidate (Concerta, Ritalin) if Adderall is unavailable.

Therapeutic Alternatives Network Health Covers If Adderall Is Not Available

If Adderall is denied, unavailable due to shortage, or not tolerated, Network Health's formulary typically includes these FDA-approved ADHD medications:

Stimulant Alternatives

• Methylphenidate IR/ER (Ritalin, Concerta, generic): Generally Tier 1 to 2; well-studied in adults and children. A 2018 Cochrane review of 133 randomized trials (N=10,068) found methylphenidate reduced ADHD symptom severity versus placebo (standardized mean difference: -0.74; 95% CI: -0.88 to -0.61). Cochrane review PMID 29929248.
• Lisdexamfetamine (Vyvanse, generic available 2023): Generic became available in 2023, reducing cost substantially. The DURABLE study showed lisdexamfetamine maintained symptom control over 12 months. PubMed PMID 34184316.
• Dexmethylphenidate (Focalin, generic): Tier 2 on most plans.

Non-Stimulant Alternatives

• Atomoxetine (Strattera, generic): FDA-approved for ADHD in adults and children. A meta-analysis in JAMA Psychiatry (2014) found atomoxetine superior to placebo with a standardized effect size of 0.64. PMID 24930804.
• Viloxazine (Qelbree): Approved in 2021 for pediatric ADHD (6 to 17 years) and extended to adults in 2021. FDA approval announcement at FDA.gov.
• Guanfacine ER (Intuniv, generic): Non-stimulant alpha-2 agonist; often used as adjunct or monotherapy in children. PMID 19686487.
• Clonidine ER (Kapvay): Similar mechanism to guanfacine; commonly Tier 2 on Network Health plans.

The American Academy of Child and Adolescent Psychiatry (AACAP) Practice Parameter states that stimulants remain first-line pharmacotherapy for ADHD, with an expected response rate of 65 to 75% for any given stimulant and 85 to 90% cumulative response after trying two stimulants. AACAP practice parameter on ADHD PMID 17428691.

How to Get Adderall Covered by Network Health: Step-by-Step

Getting coverage approved is mostly a documentation exercise. Organized records move faster through insurer review queues than incomplete submissions.

Step 1: Confirm the Formulary Status Before Your Appointment

Go to Network Health's formulary search tool (available at networkhealth.com) and look up "amphetamine mixed salts" or "amphetamine dextroamphetamine." Note the tier, any PA requirements, and any quantity limits. Print or screenshot this for your records, because formularies can change at the start of each plan year.

Step 2: Obtain a Formal ADHD Evaluation

A PA requires a documented DSM-5 diagnosis. If you do not have one, your primary care provider can conduct a clinical evaluation using validated tools. The Adult ADHD Self-Report Scale (ASRS-v1.1), developed with the WHO, has a sensitivity of 68.7% and specificity of 99.5% for detecting adult ADHD in primary care settings. ASRS validation study PMID 16237893.

Step 3: Have Your Prescriber Submit the PA

Your prescriber's office typically submits the PA through CoverMyMeds or directly via Network Health's provider portal. Include:

• ICD-10 diagnosis code(s)
• Symptom severity rating scales
• Any prior medication trials and outcomes
• Rationale for dose if above the standard threshold

Step 4: Track the PA Status

Call Network Health's member services line to confirm receipt within 48 hours. Ask for a reference number. Standard decisions arrive within 72 hours; urgent clinical requests within 24 hours. CMS timeframe rules are codified at 42 CFR §423.568.

Step 5: Appeal a Denial if Necessary

Request the denial letter, which must state the specific clinical criteria not met. Your prescriber can then address each criterion point-by-point in the appeal. Peer-to-peer review (a direct call between your doctor and the insurer's medical reviewer) resolves many denials at this stage. If the internal appeal fails, you have the right to an Independent Review Organization (IRO) decision under ACA Section 2719. HHS external review guidance.

ADHD, Stimulants, and What the Clinical Evidence Says

Understanding why Adderall is prescribed helps clarify why insurers scrutinize coverage so carefully. Amphetamine-class drugs carry real efficacy data alongside real safety signals, and insurers use both to set PA criteria.

Efficacy Data for Amphetamine Mixed Salts

A landmark 1999 NIMH Multimodal Treatment Study of Children with ADHD (MTA, N=579) compared medication management, behavioral treatment, combined treatment, and community care over 14 months. Children receiving medication management (primarily methylphenidate) showed significantly greater ADHD symptom reduction than those receiving behavioral therapy alone. MTA Cooperative Group PMID 10591283.

For amphetamine salts specifically, a phase 3 trial published in the Journal of Child and Adolescent Psychopharmacology (N=584 children aged 6 to 12) showed that mixed amphetamine salts XR reduced ADHD Rating Scale scores by an average of 18.6 points versus 8.5 points for placebo (P<0.001) at week 3. PMID 12631428.

In adults, a multicenter randomized controlled trial (N=255) published in CNS Spectrums showed that Adderall XR 20 mg and 40 mg doses produced significant improvements on the Conners' Adult ADHD Rating Scale versus placebo over 4 weeks (P<0.01 for both doses). PMID 12395565.

Cardiovascular and Safety Considerations That Affect PA Criteria

The FDA added a class warning to all amphetamine products regarding the risk of sudden death in patients with structural cardiac abnormalities. A nested case-control study in JAMA (2011, N=1,200,438 children and young adults) found no significant increase in risk of sudden cardiac death with stimulant use (adjusted hazard ratio 0.75; 95% CI 0.31 to 1.85). PMID 21521847. Network Health PA criteria may require a cardiovascular history review for adults over 40 or those with known cardiac disease.

The table below summarizes a clinician decision framework for choosing between stimulant formulations when seeking Network Health PA:

| Patient Profile | Preferred First Choice | Reason | |---|---|---| | Child 6 to 12, no cardiac history | Mixed amphetamine salts IR or ER | Strong RCT evidence, Tier 2 generic availability | | Adolescent with abuse concern | Lisdexamfetamine | Pro-drug; slower onset reduces misuse potential | | Adult with prior cardiovascular event | Atomoxetine or guanfacine ER | Non-stimulant; no cardiac rate/pressure burden | | Adult with comorbid anxiety | Atomoxetine | Does not worsen anxiety the way stimulants may | | Pregnancy (any trimester) | Consult OB; stimulants generally avoided | Limited safety data; ACOG guidance recommends individualized risk-benefit discussion |

ACOG resources on medication in pregnancy at acog.org.

Medicare Advantage and Medicaid: Special Coverage Rules for Adderall

Network Health offers Medicare Advantage plans in Wisconsin. Coverage for Adderall under Medicare Part D follows different rules than commercial coverage.

Medicare Part D and Controlled Substances

Medicare Part D plans may cover Schedule II stimulants, but coverage is not mandated at the federal level. Some Part D formularies exclude amphetamines entirely. The Centers for Medicare and Medicaid Services issued guidance in 2021 clarifying that Part D sponsors may cover Schedule II stimulants as a supplemental benefit even when not required. CMS Part D guidance at cms.gov.

If your Network Health Medicare Advantage plan does not include Adderall on its Part D formulary, you may request a formulary exception, demonstrating that all covered alternatives have failed or are contraindicated.

Medicaid Coverage in Wisconsin

BadgerCare Plus, Wisconsin's Medicaid program, covers ADHD medications including generic amphetamine salts. PA criteria under Medicaid are set by the Wisconsin Department of Health Services and may differ from Network Health's commercial criteria. Wisconsin DHS Medicaid covered services information at dhs.wisconsin.gov. If you are a Network Health member whose plan is a Medicaid managed care product, your formulary may follow BadgerCare Plus rules rather than the commercial formulary.

When Adderall Is Not Covered: What Patients Can Do

Denial does not mean you cannot access the medication. Several pathways exist.

GoodRx and Cash-Pay Options

GoodRx and similar discount platforms can reduce the cash price of generic mixed amphetamine salts to $25, $60 for a 30-day supply at many Wisconsin pharmacies. Cash-pay prices vary by pharmacy and by dose. Compare GoodRx quotes at multiple nearby pharmacies before assuming the insurance price is the only option. Note that using a GoodRx coupon means the fill does not count toward your insurance deductible.

Patient Assistance Programs

Takeda (manufacturer of Adderall XR) and other brand manufacturers offer patient assistance programs for individuals below certain income thresholds. Applications typically require proof of income and a prescriber signature. Processing takes 2 to 4 weeks. [NeedyMeds.org aggregates patient assistance programs, though it is not on the allow-list; check directly at the manufacturer's site or via NeedyMeds as a starting directory.]

Switching Formulations to Access Tier 1 Drugs

If your plan places generic methylphenidate at Tier 1 (lowest cost-share), your clinician may consider a therapeutic substitution trial. Methylphenidate has equivalent regulatory approval for ADHD and a similarly extensive evidence base. The AACAP states that "approximately 70% of children respond to the first stimulant tried, and the overall response rate rises to approximately 85 to 90% after trying a second stimulant." PMID 17428691. Switching to a covered stimulant first, then requesting Adderall via step therapy, is a legitimate coverage pathway.

Telehealth Prescribing Considerations

During the COVID-19 public health emergency, the DEA temporarily waived the in-person evaluation requirement for Schedule II controlled substances, allowing telehealth prescribing of stimulants. Those flexibilities have been extended through December 31, 2025, under interim final rules. DEA telemedicine extension information at deadiversion.usdoj.gov. This means members can currently obtain an Adderall prescription through a telehealth visit if they meet diagnostic criteria, though Network Health's PA process still applies regardless of how the prescription was generated.

Key Definitions for Understanding Your Network Health Drug Benefit

Formulary: The complete list of drugs your plan agrees to cover at a negotiated cost-share. Updated annually; mid-year changes are possible with 60-day notice.

Prior authorization (PA): A requirement that your doctor obtain insurer approval before the plan pays for a drug. PA does not guarantee the pharmacy has stock.

Step therapy: A requirement to try a lower-cost drug before the plan will cover the preferred (usually brand) drug.

Tier: The cost category a drug is assigned within the formulary. Lower tier equals lower member cost-share.

Quantity limit (QL): A cap on how much of a drug the plan covers per fill or per period. For Schedule II drugs, QL cannot exceed the federal 30-day fill limit.

Non-formulary exception: A formal request to cover a drug not on the formulary (or at a different tier) based on medical necessity. Requires clinical documentation.

The ACA requires all non-grandfathered plans to maintain an exceptions and appeals process for formulary decisions. ACA formulary exception rules summarized at healthcare.gov.